Clinical trials: Uterine Disease
Endometrial Cancer
European Collaborative Multicenter Observational Study: Modular Treatment With PMMR and Targeted Compartmental Pelvic Lymphadenectomy Followed by Therapeutic Pelvic and Paraaortic Lymphadenectomy in Node Positive Disease for Locoregional Control in Endometrial Cancer FIGO Stages I-III
Intermediate/high risk endometrial cancer shows locoregional recurrence rates up to 20%. Also in so called low-risk disease 5-10% incidence of nodal metastasis is reported.
- Trial name
- PMMR (NCT04504006)
- Testing
- Peritoneal Mesometrial Resetion + Targeted Compartmental Lymphadenectomy (PMMR+TCL)
- Where
- Germany
- Volunteers
- 500 people
- Sponsor
- Dr. Paul Buderath
Stage I Endometrial Carcinoma, Stage II Endometrial Carcinoma
Lymph Node Mapping in Patients With Newly Diagnosed Endometrial Cancer Undergoing Surgery
This clinical trial studies lymph node mapping in patients with newly diagnosed endometrial cancer undergoing surgery. Lymph node mapping may help in planning surgery to remove endometrial cancer and affected lymph nodes.
- Conditions
- Stage I Endometrial Carcinoma, Stage II Endometrial Carcinoma, Stage III Endometrial Carcinoma, Stage IV Endometrial Carcinoma
- Trial name
- NCT01939028
- Testing
- lymph node mapping, sentinel lymph node biopsy, isosulfan blue
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- Case Comprehensive Cancer Center
Endometrial Cancer Stage
Investigation Of Receptivity Markers For Endometrial Cancer Treatment Development
Hyaluronan is an extracellular matrix protein that is involved in cell-cell and cell-matrix interactions. Hyaluronan performs this activity through hyaladherins, which are intracellular and extracellular receptors.
- Trial name
- NCT05914844
- Where
- Turkey (Türkiye)
- Volunteers
- 30 people
- Sponsor
- Manisa Celal Bayar University
Gynecologic Cancer, Gynecologic Neoplasm
Patient-Reported Outcomes Among Women Wtih Gynecological Cancer (The CONNECT Study)
Systematic nurse-led consultations based on electronic patient-reported outcomes (ePRO) will be tested among women with ovarian - and endometrial cancer receiving first-line chemotherapy.
- Conditions
- Gynecologic Cancer, Gynecologic Neoplasm, Ovarian Cancer, Endometrial Cancer
- Trial name
- NCT04945187
- Testing
- Nurse-led consultations based on electronic patient-reported outcomes
- Where
- Denmark
- Volunteers
- 94 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
HIV, Cervical Cancer
Community, Home-based Education, Screening Services Strategy to Increase Cervical Cancer Control Access for HIV-Positive Women in Nigeria
The goal of this observational study is to focus on adapting and implementing a program to promote HPV and cervical cancer (CC) screening and follow-up treatment for HIV-positive women, with three specific aims: Adaptation: Use…
- Trial name
- NCT06751030
- Testing
- The Mother Mentor program, GeneXpert HPV test
- Where
- 3 sites in Nigeria
- Volunteers
- 1,500 people
- Sponsor
- Emory University
Uterine Leiomyomata (Fibroids)
Study Evaluating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PRA-027 in Japanese Postmenopausal Women
The primary purpose of this study is to assess the safety and tolerability of ascending, multiple, oral doses of PRA-027 in Japanese postmenopausal women.
- Trial name
- NCT00826436
- Where
- Japan
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Third Stage of Delivery
Maternal Outcomes Following Manual Lysis of the Placenta.
Comparison of maternal outcomes following manual lysis of placenta 15 vs 30 minutes after delivery. A primary outcome of the drop in hemoglobin will be compared between the two groups.
- Trial name
- NCT03626844
- Testing
- Manual Lysis of Placenta after 15 minutes (Intervention), Manual Lysis of Placenta after 30 minutes (Control)
- Where
- Israel
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Holy Family Hospital, Nazareth, Israel
Neoplasms, Solid Tumors
An Exploratory Study of Zanidatamab in HER2-positive Advanced Tumor After at Least One Line of Standard Therapy
The goal of this clinical trial is to learn if Zanidatamab can treat HER2-positive advanced tumors in adults. The main question it aims to answer is: What is the objective response rate of Zanidatamab in adult patients with HER-2…
- Conditions
- Neoplasms, Solid Tumors, HER2 Positive Solid Tumor, Endometrial Neoplasm
- Trial name
- NCT07631871
- Testing
- Zanidatamab
- Volunteers
- 10 people
- Sponsor
- Haihua Yuan
Recurrent or Metastatic Solid Tumors
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXD) in the following tumor types: endometrial cancer (EC); head and neck squamous cell carcinoma (HNSCC); pancreatic ductal adenocarcinoma…
- Trial name
- NCT06330064
- Testing
- Ifinatamab deruxtecan
- Where
- 120 sites in United States, Argentina and 16 more
- Volunteers
- 680 people
- Sponsor
- Daiichi Sankyo
Cervical Cancer
Study of ZG005 in Combination With Gecacitinib in Participants With Advanced Cervical Cancer
This is a multicenter, open-label phase I/II study in patients with advanced cervical cancer designed to evaluate the safety, tolerability, and preliminary efficacy of ZG005 in combination with Gecacitinib ± bevacizumab.
- Trial name
- NCT07080216
- Testing
- ZG005, Gecacitinib, Bevacizumab
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Lymphedema of Leg, Cancer of Cervix
High Intensity Interval Training (HIIT) for Patients With Cancer-related Lymphedema in the Lower Limbs
The aim of the study is to explore the feasibility and safety of High Intensity Interval Training on a stationary bike for patients with lymphedema in the lower limbs and the role of compression garments during exercise.
- Conditions
- Lymphedema of Leg, Cancer of Cervix, Cancer, Ovarian, Cancer, Endometrial
- Trial name
- NCT03653819
- Testing
- First exercise session + compression, First exercise session - compression
- Where
- Denmark
- Volunteers
- 20 people
- Sponsor
- Herlev and Gentofte Hospital
Endometrial Cancer, Uterine Cancer
A Study Assessing the Safety and Utility of PINPOINT® Near Infrared Fluorescence Imaging in the Identification of Lymph Nodes in Patients With Uterine and Cervical Malignancies Who Are Undergoing Lymph Node Mapping
This is a randomized, prospective, open label, multicenter study to assess the safety and utility of PINPOINT® Near Infrared Fluorescence Imaging (PINPOINT) in identification of lymph nodes (LN) in patients with uterine and…
- Conditions
- Endometrial Cancer, Uterine Cancer, Cervical Cancer
- Trial name
- FILM (NCT02209532)
- Testing
- PINPOINT
- Where
- 8 sites in United States, Canada and 1 more
- Volunteers
- 180 people
- Sponsor
- Novadaq Technologies ULC, now a part of Stryker
Endometriosis, Adenomyosis
Clinical and Molecular Study of Endometriosis and Adenomyosis
The purpose of this study is to determine whether endometriosis and adenomyosis are progressive diseases, in terms of symptoms (pain, abnormal uterine bleeding and infertility), anatomical lesions size, and recurrences.
- Trial name
- ENDOCHAP (NCT04481321)
- Testing
- Biological/Vaccine
- Where
- France
- Volunteers
- 5,300 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Colorectal Carcinoma (CRC), Endometrial Carcinoma (EC)
Pilot Window of Opportunity Trial (POET)
The proposed clinical trial with TPST-1495 can help people with two types of cancer, Endometrial Cancer (EC) and Colorectal Carcinoma (CRC), who need surgery.
- Trial name
- NCT06129604
- Testing
- TPST-1495
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Oklahoma
Renal Cell Carcinoma, Urothelial Carcinoma
Famitinib Plus Anti-PD1 Therapy for Advanced Urinary System Tumor, Advanced Gynecological Tumors
Phase II multi-chort, adaptive two-stage, open label, nonrandomized study. The aim of our study is to evaluate the efficacy and safety of anti-PD-1 antibody SHR-1210(Camrelizumab) in combination with a small-molecule multikinase…
- Conditions
- Renal Cell Carcinoma, Urothelial Carcinoma, Cervical Cancer, Ovarian Cancer Recurrent
- Trial name
- NCT03827837
- Testing
- SHR-1210, Famitinib
- Where
- China
- Volunteers
- 265 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Menorrhagia, Heavy Menstrual Bleeding
Efficacy and Safety of XP12B in Women With Menorrhagia
The purpose of this study is to determine whether XP12B is effective and safe in the treatment of women with heavy menstrual bleeding associated with menorrhagia.
- Trial name
- NCT00401193
- Testing
- Tranexamic acid tablets
- Where
- 83 sites in United States
- Volunteers
- 304 people
- Sponsor
- Ferring Pharmaceuticals
Ovarian Cancer, Sarcoma
Combination Chemotherapy in Treating Patients With Sarcoma
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00662233
- Testing
- cyclophosphamide, doxorubicin hydrochloride, etoposide
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Mayo Clinic
Anesthesia, Cervical Cancer
Effects of Anesthesia on Tumor Immunity and Insulin Resistance During Perioperative Period
To evaluate the effects of preoperative oral carbohydrate on postoperative insulin resistance and tumor immunity in cervical cancer patients with neoadjuvant chemotherapy.
- Conditions
- Anesthesia, Cervical Cancer, Carbohydrate, Tumor Immunity
- Trial name
- NCT03872635
- Testing
- oral carbohydrate liquid
- Where
- 2 sites in China
- Volunteers
- 80 people
- Sponsor
- Fujian Cancer Hospital
Endometritis
The Pharmacokinetics of Azithromycin Prophylaxis for Cesarean Delivery
PKAZ is a single institution study designed to evaluate the optimal dosing parameters for azithromycin for pre-surgical cesarean prophylaxis.
- Trial name
- PKAZ (NCT01464840)
- Testing
- Azithromycin
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
NSCLC (Non-small Cell Lung Cancer), HNSCC
A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors
A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects with Select Advanced Solid Tumors.
- Conditions
- NSCLC (Non-small Cell Lung Cancer), HNSCC, Endometrial, Ovarian Cancer
- Trial name
- NCT07814248
- Testing
- TS-104
- Where
- 3 sites in United States
- Volunteers
- 74 people
- Sponsor
- TwoStep Therapeutics, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.